159 related articles for article (PubMed ID: 34321417)
1. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis.
Kian W; Zemel M; Elobra F; Sharb AA; Levitas D; Assabag Y; Alguayn F; Yakobson A; Rouvinov K; Fuchs L
Anticancer Drugs; 2022 Jan; 33(1):e738-e740. PubMed ID: 34321417
[TBL] [Abstract][Full Text] [Related]
2. Toxic epidermal necrolysis associated with pembrolizumab.
Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab induced toxic epidermal necrolysis.
Kumar R; Bhandari S
Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
[No Abstract] [Full Text] [Related]
4. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
[TBL] [Abstract][Full Text] [Related]
5. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
Hwang A; Iskandar A; Dasanu CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
[TBL] [Abstract][Full Text] [Related]
6. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
7. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
[TBL] [Abstract][Full Text] [Related]
8. [Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome].
Kühn-Córdova I; Ramírez-Bouchan D; Gamboa-Marrufo JD
An Pediatr (Barc); 2007 Jul; 67(1):68-73. PubMed ID: 17663910
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report.
Robinson S; Saleh J; Curry J; Mudaliar K
Am J Dermatopathol; 2020 Apr; 42(4):292-296. PubMed ID: 31567395
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
11. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
[TBL] [Abstract][Full Text] [Related]
12. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
[TBL] [Abstract][Full Text] [Related]
13. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
14. [A Case in Which Toxic Epidermal Necrosis Developed during Treatment with the Immune Checkpoint Inhibitor Pembrolizumab for Recurrent Patients Following Lung Cancer Surgery].
Tsujita T; Takahashi S; Oinuma T; Hata N
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1641-1644. PubMed ID: 30449854
[TBL] [Abstract][Full Text] [Related]
15. A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment.
Oguri T; Sasada S; Shimizu S; Shigematsu R; Tsuchiya Y; Ishioka K; Takahashi S; Oki K; Kimura Y; Seki R; Hirose S; Nakamura M
J Investig Med High Impact Case Rep; 2021; 9():23247096211037462. PubMed ID: 34344201
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Blanchard A; Bouchard N
Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
[TBL] [Abstract][Full Text] [Related]
17. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases.
Comparin C; Hans Filho G; Takita LC; Costa Nde C; Nascimento RA; Nanni Lde O
An Bras Dermatol; 2012; 87(3):477-81. PubMed ID: 22714769
[TBL] [Abstract][Full Text] [Related]
18. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
19. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
